These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28240046)

  • 1. "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.
    Malik T; Chauhan G; Rath G; Murthy RS; Goyal AK
    Drug Deliv; 2017 Nov; 24(1):608-621. PubMed ID: 28240046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of viral entry.
    Melby T; Westby M
    Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HIV attachment and entry for therapy.
    Strizki J
    Adv Pharmacol; 2008; 56():93-120. PubMed ID: 18086410
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
    Mostashari Rad T; Saghaie L; Fassihi A
    Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral nanoparticles: an extended drug delivery modality.
    Destache CJ; Goede M; Belgum T
    Ther Deliv; 2010 Sep; 1(3):383-6. PubMed ID: 22816141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HIV-1 by fusion inhibitors.
    Eggink D; Berkhout B; Sanders RW
    Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review).
    Venanzi Rullo E; Ceccarelli M; Condorelli F; Facciolà A; Visalli G; D'Aleo F; Paolucci I; Cacopardo B; Pinzone MR; Di Rosa M; Nunnari G; Pellicanò GF
    Mol Med Rep; 2019 Mar; 19(3):1987-1995. PubMed ID: 30628713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections.
    Sepúlveda-Crespo D; Ceña-Díez R; Jiménez JL; Ángeles Muñoz-Fernández M
    Med Res Rev; 2017 Jan; 37(1):149-179. PubMed ID: 27518199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting HIV fusion: identifying novel targets for entry inhibitors.
    Finnegan C; Blumenthal R
    Infect Disord Drug Targets; 2006 Dec; 6(4):355-67. PubMed ID: 17168801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How entry inhibitors synergize to fight HIV.
    Melikyan GB
    J Biol Chem; 2017 Oct; 292(40):16511-16512. PubMed ID: 28986430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
    Flores A; Quesada E
    Curr Med Chem; 2013 Feb; 20(6):751-71. PubMed ID: 23278399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
    Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
    Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
    Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
    Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The HIV replication cycle. Established therapeutic targets and potential targets].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():3-10. PubMed ID: 19572419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.